Back to Basics? | GenomeWeb

Back to Basics?

Analyst Tim Anderson says that Pfizer could cut back to become strictly a drug discovery firm. To do so, the company would have to strip itself of "divisions accounting for $32 billion of its $67 billion in sales," adds Matthew Herper at Forbes. Anderson says these "extremely bold" moves would be greeted warmly by investors, though Pfizer has not made any commitments one way or the other.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Related Posts

And, Poof, It's Gone

Changes Ahead

Promising Trial

To Spot it Early

Cancer Trial Halted

In Science this week: global genetic diversity map, and more.

The Nuffield Council on Bioethics identifies ethical questions to explore surrounding genome editing.

In a blog post, Brigham and Women's Hospital's Robert Green discusses "predispositional personal genome sequencing."

Stat News reports that there's muted opposition to the Kuwaiti DNA database law.